1. Home
  2. EXP vs GPCR Comparison

EXP vs GPCR Comparison

Compare EXP & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eagle Materials Inc

EXP

Eagle Materials Inc

HOLD

Current Price

$173.11

Market Cap

7.0B

Sector

Industrials

ML Signal

HOLD

Logo Structure Therapeutics Inc.

GPCR

Structure Therapeutics Inc.

HOLD

Current Price

$48.23

Market Cap

6.3B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
EXP
GPCR
Founded
1963
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Building Materials
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
7.0B
6.3B
IPO Year
1994
2023

Fundamental Metrics

Financial Performance
Metric
EXP
GPCR
Price
$173.11
$48.23
Analyst Decision
Hold
Strong Buy
Analyst Count
9
11
Target Price
$226.44
$103.36
AVG Volume (30 Days)
400.7K
829.0K
Earning Date
01-29-2026
05-07-2026
Dividend Yield
0.56%
N/A
EPS Growth
1.18
N/A
EPS
11.21
N/A
Revenue
$495,023,000.00
N/A
Revenue This Year
$1.84
N/A
Revenue Next Year
$1.69
N/A
P/E Ratio
$15.83
N/A
Revenue Growth
N/A
N/A
52 Week Low
$175.59
$13.24
52 Week High
$243.64
$94.90

Technical Indicators

Market Signals
Indicator
EXP
GPCR
Relative Strength Index (RSI) 21.01 24.82
Support Level N/A $18.36
Resistance Level $239.71 $93.91
Average True Range (ATR) 5.68 3.50
MACD -2.66 -0.60
Stochastic Oscillator 2.54 3.01

Price Performance

Historical Comparison
EXP
GPCR

About EXP Eagle Materials Inc

Eagle Materials Inc produces and sells construction products and building materials. Construction products include cement, slag, concrete, and aggregates and building materials include cement and gypsum wallboard, and are sold to the construction and building industries. The firm organizes itself into two sectors: Heavy Materials, which includes the Cement and Concrete and Aggregates segments, and Light Materials, which includes the Gypsum Wallboard and Recycled Paperboard segments.

About GPCR Structure Therapeutics Inc.

Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.

Share on Social Networks: